The North American experience with photopheresis.

摘要: Photopheresis or extracorporeal photochemotherapy (ECP) is a novel immunomodulatory therapy based upon pheresis of light-sensitive cells. Whole blood removed from patients who have previously ingested the photosensitizing agent 8-methoxypsoralen (8-MOP) followed by leukapheresis and exposure 8-MOP containing white cells (WBCs) extracorporeally to an ultraviolet A (UVA) light source prior their return patient. In 1988, Food Drug Administration (FDA) approved photopheresis for treatment cutaneous T-cell lymphoma (CTCL). Treatment CTCL with has been reported in over 300 worldwide. also demonstrated encouraging results solid organ transplant rejection, graft versus host disease, scleroderma, other autoimmune diseases although fewer studied. This review will focus on North American experience photopheresis.